Improving treatment for patients with resistant acute myeloid leukemia using venetoclax.
Enhancing Venetoclax Activity in Chemoresistant Acute Myeloid Leukemia
This study is looking at how to make the leukemia drug venetoclax work better for patients whose cancer has stopped responding to regular treatments, with the hope of finding new ways to help them feel better and improve their chances of recovery.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10798131 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of venetoclax, a medication used to treat acute myeloid leukemia (AML), particularly in patients whose cancer has become resistant to standard treatments. The project aims to understand the biological mechanisms behind this resistance and to develop new strategies that could improve patient outcomes. By utilizing advanced biological assays, the research seeks to identify how venetoclax can be better utilized in combination with other therapies to combat relapsed AML. Patients may benefit from insights gained through this research that could lead to more effective treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have experienced relapse or resistance to previous treatments.
Not a fit: Patients with acute myeloid leukemia who are newly diagnosed and have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with chemoresistant acute myeloid leukemia, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promise in enhancing the effectiveness of venetoclax in similar patient populations, indicating that this approach may yield beneficial results.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Garcia, Jacqueline Suen — Dana-Farber Cancer Inst
- Study coordinator: Garcia, Jacqueline Suen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.